ILARIS® (canakinumab) safety profile

Indications¹

Periodic fever syndromes
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

• Cryopyrin-associated periodic syndromes (CAPS), including:

  • Muckle-Wells syndrome (MWS)

  • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)

  • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash

• Tumour necrosis factor receptor associated periodic syndrome (TRAPS)

• Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)

• Familial Mediterranean Fever (FMF)

  • ILARIS should be given in combination with colchicine, if appropriate

Still’s disease
ILARIS is indicated in patients who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids, for the treatment of active Still’s disease, including:

• Adult-onset Still’s disease (AOSD) 

• Systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older 

• ILARIS can be given as monotherapy or in combination with methotrexate 

Gouty arthritis
ILARIS is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.